Lucile Blaise will become president of ResMed’s Sleep & Respiratory Care business on July 1. [Photo courtesy of ResMed]
Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today.
She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during the transition.
Blaise is ResMed’s VP of Sleep & Respiratory Care for Western Europe. She joined San Diego-based ResMed in 2006 and has more than 25 years of experience in medical device sales, marketing, finance, and business development, the company said in a news release.
Blaise serves on the MedTech Europe board and was elected president of French medtech association Snitem this month.
ResMed CEO Mick Farrell called Blaise “one of Europe’s leading champions of digital health innovation and adoption, as well as data privacy and security.”
“Lucile has been a key player in improving chronic disease treatment for millions of people with sleep apnea and respiratory insufficiency, as well as supporting physicians, providers, and healthcare systems across Europe, and beyond, through evidence-based decision making,” Farrell said in a news release. “Lucile is committed to collaboration across the company, and the industry, and always places the needs of the patient first. She exemplifies the deep bench of innovative, accomplished leaders across ResMed, bringing in-depth market knowledge, customer insight, and commercial skills to our CEO operations leadership team, as together we continue to transform our business and the market through digital health.”
ResMed is the 34th-largest medtech company in the world, according to Medical Design & Outsourcing‘s latest Big 100 ranking by revenue.
ResMed’s big story has been its efforts to overcome a global shortage of semiconductors to capitalize on a massive recall by competitor Philips Respironics. Philips just today released results from product safety testing, and the recall is expected to last well into 2023 under the scrutiny of the FDA and Department of Justice investigators.